Acquisition - January 6, 2025
Combinostics and SyntheticMR join forces
Before Christmas Finnish Combinostics announced that it has entered an agreement with the Swedish company SyntheticMR where SyntheticMR will acquire all shares in Combinostics.
Agreement - December 19, 2024
BioArctic enters global license agreement with Bristol Myers Squibb
BioArctic has entered into a global exclusive license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic’s BrainTransporter technology.
Acquisition - December 18, 2024
Ultimovacs combines its business with Zelluna Immunotherapy
Ultimovacs and Zelluna Immunotherapy have announced that Ultimovacs and shareholders of Zelluna representing more than 99% of the total number of issued and outstanding shares in Zelluna have entered into a definitive business combination agreement to combine the two companies in a share exchange transaction.
Agreement - December 2, 2024
Orexo and GAIA terminate partnership for Deprexis
The two companies have decided to terminate the partnership agreement, covering the rights for Orexo to commercialize the digital mental health program for depression, Deprexis, in the US.
Agreement - November 11, 2024
ALK licenses rights to neffy
ALK has entered into a strategic license agreement with US-based ARS Pharmaceuticals.
Agreement - November 4, 2024
Ascendis Pharma and Novo Nordisk collaborate
Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.
